PYXS MICVO posts 36% response rate and 6.2-month PFS in HNSCC
MICVO showed a 36% response rate and 6.2-month median PFS in 2L+ R/M HNSCC. Safety was manageable, with late-onset, reversible neuropathy. Phase 3 initiation is planned for mid-2027.
2-month median PFS in 2L+ R/M HNSCC, versus historical controls. Safety was manageable, with late-onset, reversible neuropathy. Phase 3 initiation is planned for mid-2027. The original document appears truncated after “Pyxis On…”.